Tech Company Financing Transactions
Apellis Pharmaceuticals Funding Round
Morningside Group, AJU IB Investment and Epidarex Capital joined a $33 million venture round for Apellis Pharmaceuticals. The round was announced by the company on 12/2/2014.
Transaction Overview
Company Name
Announced On
12/2/2014
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds will be used to fund three new complement immunotherapy programs entering clinical proof-of-concept stage.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6400 Westwind Way A
Crestwood, KY 40014
USA
Crestwood, KY 40014
USA
Phone
Website
Email Address
Overview
Apellis (NASDAQ: APLS) was founded in 2009. Apellis' approach is centered on the inhibition of the complement system, which is a cascade of interacting proteins and is an integral component of the immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cedric Francois
Chief Financial Officer
Timothy Sullivan
Chief Medical Officer
Federico Grossi
Chief Operating Officer
Pascal Deschatelets
VP - Finance
Nicole Perry
VP - General Counsel
David Watson
VP - Operations
Ahmad Sadr
Browse more venture capital transactions:
Prev: 12/2/2014: CareLinx venture capital transaction
Next: 12/2/2014: Conventus Orthopaedics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs